Cephalon

By Larry, of Hedge Fund Live - Teva recently announced a buy out of Cephalon for $6.8B and the markets seems to view this positively as both companies' stock rose in early morning trading. It was an interesting announcement considering that just days before the EU regulators were going to...

Gabelli has issued a report on Valeant Pharmaceuticals' (NYSE: VRX) offer to acquire Cephalon for $73 a share, $5.7 billion total. According to Gabelli, “Valeant Pharmaceuticals (NYSE: VRX) is offering $73 per share for Cephalon ($5.7 billion in total) – call at 8:30am… Cephalon has a strong...

Piper Jaffray is reiterating its Neutral rating and $58 PT on shares of Cephalon Inc. (NASDAQ: CEPH). “Last night, Valeant announced that it is making an unsolicited offer to acquire Cephalon for $73 per share in an all-cash transaction that values the company at $5.7B,” Piper Jaffray writes. “We...

Caris & Company has upgraded Cephalon (NASDAQ: CEPH) from Below Average to Average.

In a report published by Jefferies, Cephalon (NASDAQ: CEPH) continues its collection of little known companies and assets. Jefferies said that Gemin X's lead candidate has finished Phase II in lung cancer, and although CEPH's look at the data was inspiring enough to spend $225M upfront (additional...

Oppenheimer is out with its report today on Cephalon (NASDAQ: CEPH), maintaining Perform. In a note to clients, Oppenheimer writes, "Our Perform rating is based on lower Nuvigil sales expectations and moderated expectations for the drug's success in bipolar depression. Based on our current DCF...

J.P. Morgan is out with its report today on Cephalon (NASDAQ: CEPH), maintaining Neutral. In a note to clients, J.P. Morgan writes, "With a growing late stage pipeline but with anticipated severe pressure to postgeneric Provigil entry 2012-2013 EPS estimates, we rate Cephalon shares Neutral with a...

Oppenheimer has published a research report on Cephalon (NASDAQ: CEPH) and has downgraded the company from Outperform to Perform. In the report, Oppenheimer writes "Based on results from a proprietary Provigil/Nuvigil physician survey and our analysis of Nuvigil's prospects in bipolar depression,...

Jefferies & Company has downgraded Cephalon (NASDAQ: CEPH) from Buy to Underperform and has lowered the price target from $77 to $48.

JP Morgan has downgraded Cephalon, Inc. (NASDAQ: CEPH) from Overweight to Neutral and has lowered the price target from $73 to $65.

Goldman Sachs is reiterating its Neutral rating on Cephalon (NASDAQ: CEPH) after strong Q4 EPS. “Cephalon reported diluted EPS of $2.19, above our $2.05 estimate and the Street at $1.93,” Goldman Sachs comments. The report also added, “bottom line, we see little new from 4Q to influence the post...